tradingkey.logo

Organon & Co

OGN
View Detailed Chart

10.450USD

-0.400-3.69%
Close 09/19, 16:00ETQuotes delayed by 15 min
2.72BMarket Cap
3.88P/E TTM

Organon & Co

10.450

-0.400-3.69%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.69%

5 Days

-1.88%

1 Month

+12.85%

6 Months

-33.82%

Year to Date

-29.96%

1 Year

-48.22%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
23 / 175
Overall Ranking
103 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Hold
Current Rating
12.800
Target Price
+17.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 34.38%.
Undervalued
The company’s latest PE is 3.85, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 205.34M shares, decreasing 19.74% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 32.15M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
Ticker SymbolOGN
CompanyOrganon & Co
CEOMr. Kevin Ali
Websitehttps://www.organon.com/
KeyAI